论文部分内容阅读
目的研究生脉注射液防治表柔比星心肌毒性的疗效。方法治疗组与对照组均予CAP方案辅助化疗,治疗组于化疗开始前2 d予生脉注射液60 mL每日1次静点,连用15 d。结果治疗组心电图异常比率为2%,对照组为20%,2组比较有显著性差异。治疗组与对照组左室射血分数比较有显著性差异(P<0.05),生脉注射液减轻了表柔比星对心脏EF的影响。结论生脉注射液可防治表柔比星的心肌毒性,为临床上适当加大表柔比星的化疗剂量,提高疗效提供了可能。
Objective To study the effect of Shengmai Injection in preventing epirubicin-induced myocardial toxicity. Methods The patients in the treatment group and the control group received adjuvant chemotherapy with CAP regimen. The patients in the treatment group were injected Shengmai Injection 60 mL once daily once daily for 15 days before the start of chemotherapy. Results The electrocardiographic abnormality rate was 2% in the treatment group and 20% in the control group. There was significant difference between the two groups. The LV ejection fraction of the treatment group and the control group were significantly different (P <0.05). Shengmai Injection reduced the effect of epirubicin on the cardiac EF. Conclusion Shengmai injection can prevent epirubicin myocardial toxicity, which is clinically appropriate to increase the dose of epirubicin chemotherapy to improve the efficacy.